Legal & General Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Legal & General Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,749	Closed	-$40K	–	3543
2020 Q4	$40K	Sell	1,749 -44	-2%	-$558	﹤0.01%	2867
2020 Q3	$18K	Sell	1,793 -487	-21%	-$6.53K	﹤0.01%	3015
2020 Q2	$34K	Buy	2,280 +134	+6%	+$2.06K	﹤0.01%	2843
2020 Q1	$26K	Buy	2,146 +716	+50%	+$11.4K	﹤0.01%	2822
2019 Q4	$23K	Buy	1,430 +228	+19%	+$2.91K	﹤0.01%	3148
2019 Q3	$15K	Buy	+1,202	New	+$13.6K	﹤0.01%	3207

Legal & General Group's PRVL Position: Q1 2021 in Review

Legal & General Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,749 shares — an estimated $40K sold.

Legal & General Group first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $40K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Legal & General Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Legal & General Group sold 1,749 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $40K.
Legal & General Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Legal & General Group's Prevail Therapeutics Inc. Common Stock position peaked at $40K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Legal & General Group's 13F filing for Q1 2021, filed 17 May 2021.